118 related articles for article (PubMed ID: 709524)
1. Carcinoembryonic antigen in breast cancer.
Myers RE; Sutherland DJ; Meakin JW; Kellen JA; Malkin DG; Malkin A
Cancer; 1978 Sep; 42(3 Suppl):1520-6. PubMed ID: 709524
[TBL] [Abstract][Full Text] [Related]
2. Serial tests of carcinoembryonic antigen in patients with breast cancer.
Lee YT
Am J Clin Oncol; 1983 Jun; 6(3):287-93. PubMed ID: 6846246
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of elevated CEA values in the follow-up management of patients with breast cancer].
Paulick R; Caffier H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):774-9. PubMed ID: 4076751
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma.
Haagensen DE; Kister SJ; Vandevoorde JP; Gates JB; Smart EK; Hansen HJ; Wells SA
Cancer; 1978 Sep; 42(3 Suppl):1512-9. PubMed ID: 709523
[TBL] [Abstract][Full Text] [Related]
5. [Our experience with the diagnostic and prognostic unreliability of pre- and postoperative CEA in human breast cancer].
Ovaleo-Pandolfo E; Capelli P; Franciosi V
Acta Biomed Ateneo Parmense; 1985; 56(2):91-8. PubMed ID: 2930984
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum carcinoembryonic antigen and prognosis of breast cancer patients postmastectomy.
Paulick R; Caffier H
Cancer Detect Prev; 1988; 11(3-6):311-7. PubMed ID: 3390852
[TBL] [Abstract][Full Text] [Related]
7. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen in gastric cancer patients.
Shimizu N; Wakatsuki T; Murakami A; Yoshioka H; Hamazoe R; Kanayama H; Maeta M; Koga S
Oncology; 1987; 44(4):240-4. PubMed ID: 3614814
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen as a monitor of recurrent breast cancer.
Lee YT
J Surg Oncol; 1982 Jun; 20(2):109-14. PubMed ID: 7078191
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of CEA studies in patients with benign and malignant breast diseases with special reference to oncologic after care].
Kunze M; Voss P; Büttner HH; Stranz G; Strache RR
Zentralbl Gynakol; 1987; 109(24):1517-26. PubMed ID: 3442160
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
17. Tissue and plasma carcinoembryonic antigen in early breast cancer. A prognostic factor.
Mansour EG; Hastert M; Park CH; Koehler KA; Petrelli M
Cancer; 1983 Apr; 51(7):1243-8. PubMed ID: 6825048
[TBL] [Abstract][Full Text] [Related]
18. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
